Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3

Status

Completed 3

Sponsor Class

NIH 5INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Breast 1

Conditions

Recurrence 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × ispinesib × Clear all
NCT00089973 2018-02-26

Study Of Ispinesib In Subjects With Breast Cancer

GlaxoSmithKline

Phase 2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms

NCT00085813 2010-10-04

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

GlaxoSmithKline

Phase 2 Completed
70 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00097409 2010-10-04

Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer

GlaxoSmithKline

Phase 2 Completed
35 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡